The reduction in the price target from $35 to $19 by HC Wainwright & Co. could lead to a negative short-term impact on Novavax's stock price. This adjustment reflects a significant change in the firm's valuation of the company, which might be interpreted by the market as a decrease in confidence in Novavax's future financial performance or growth prospects, despite maintaining a Buy rating.